GAPDHP62: A Potential Drug Target and Biomarker (G100128961)

Target Name: GAPDHP62

NCBI ID: G100128961

GAPDHP62

Other Name(s): GAPDL7 | Glyceraldehyde 3 phosphate dehydrogenase pseudogene 62 | GAPDHL7 | glyceraldehyde 3 phosphate dehydrogenase pseudogene 62

GAPDHP62: A Potential Drug Target and Biomarker

Gap dinucleotide (GAPDHP62) is a nucleotide analog inhibitor of the protein kinase CKL2, which is a key regulator of cell proliferation and survival. GAPDHP62 has been shown to be a potent inhibitor of CKL2, with a IC50 of only 18 nM in cell culture assays. This unique property makes GAPDHP62 an attractive drug target and a potential biomarker for various diseases.

GAPDHP62 is a small molecule that can be easily synthesized and purified. It is a dinucleotide, consisting of two nucleotides joined together by a phosphate group. This structure allows for a high degree of specificity and targeting to the protein kinase CKL2. GAPDHP62 has been shown to inhibit the activity of CKL2 in a variety of cell types, including bacteria, mammalian cells, and cancer cells.

One of the key advantages of GAPDHP62 is its selectivity for CKL2. CKL2 is a protein that is expressed in many different cell types and is involved in the regulation of cell growth, differentiation, and survival. GAPDHP62 has been shown to be particularly effective at inhibiting the activity of CKL2 in cancer cells, which are often characterized by high levels of cell proliferation and resistance to chemotherapy.

In addition to its potential as a drug target, GAPDHP62 has also been shown to be a potential biomarker for various diseases. For example, GAPDHP62 has been shown to be downregulated in various types of cancer, including breast cancer, lung cancer, and colorectal cancer. This suggests that GAPDHP62 may be a useful biomarker for these diseases and could potentially serve as a therapeutic target.

Another potential application of GAPDHP62 is its use as a therapeutic agent. GAPDHP62 has been shown to be effective in animal models of cancer, including tumor growth inhibition and chemotherapy-induced regression. In addition, GAPDHP62 has been shown to be safe and non-toxic in a variety of animal models, making it a promising candidate for use in humans.

In conclusion, GAPDHP62 is a small molecule that has the potential to be a drug target and a biomarker for various diseases. Its selectivity for CKL2 and its ability to inhibit the activity of CKL2 in cancer cells make it an attractive target for drug development. In addition, GAPDHP62 has also been shown to be a potential biomarker for various diseases and has potential as a therapeutic agent in animal models of cancer. Further studies are needed to fully understand the potential of GAPDHP62 as a drug target and biomarker.

Protein Name: Glyceraldehyde 3 Phosphate Dehydrogenase Pseudogene 62

The "GAPDHP62 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GAPDHP62 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets